• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 27, 2014

View Archived Issues

Sneeze breeze? No FDA ragweed quibbles for Merck, Alk-Abello

Briefing papers for the meeting next week of the FDA’s Allergenic Products Advisory Committee suggest that the panel will green-light the sublingual ragweed allergy therapy from Alk-Abello A/S and Merck and Co. Inc., just as the grass-pollen allergy tablet sailed through last month. Read More

Bench Press: BioWorld looks at translational medicine

To biopharma folks, poly(ADP-ribose) polymerase-1 (PARP-1) is best known as a synthetic lethal gene in BRCA-mutated cells. But scientists at the Mount Sinai School of Medicine have shown that PARP-1 plays a role in a very different disease, namely addiction. Read More

Genmab raises $183M for pipeline, acquisitions

Taking advantage of a strong share price performance over the past 12 months, Genmab A/S added DKK998 million (US$183 million) to its coffers in an accelerated book-build involving selected institutional investors. Read More

Australia’s Hatchtech ‘itching’ to partner at J.P. Morgan

As always, the 32nd Annual J.P. Morgan (JPM) Healthcare Conference offered an unparalleled partnering playground for pharmas and biotechs. Although the big players generated most of the headlines, hundreds of smaller companies looked to JPM as the setting where they might punch their ticket to success. Read More

Sex hormone controls blood stem cells

Sex organs are controlled by sex hormones, to nobody’s surprise – that’s their point. But now, researchers have shown that blood, too, is affected by sex hormones. Read More

Beyond the ‘Horizant’: Xenoport adds $72M in upsized offering

On the heels of encouraging FDA feedback for a multiple sclerosis program and the possibility of profitability for marketed drug Horizant (gabapentin enacarbil) by the end of 2015, Xenoport Inc. is padding its coffers with a $72 million bumped-up public offering. Read More

Other news to note

Endocyte Inc., of West Lafayette Ind., provided an update regarding the review of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the pending European Union conditional marketing authorization applications for vintafolide, etarfolatide and intravenous folic acid. Read More

Stock Movers

Read More

Financings roundup

Emergent Biosolutions Inc., of Rockville, Md., said it priced its offering of $215 million aggregate principal amount of convertible senior notes due 2021 in a private placement to qualified institutional buyers. Read More

Clinic roundup

E-Therapeutics plc, of Oxford, UK, said patient recruitment into Phase I trials of ETS2101 in brain cancer and in solid tumors was halted temporarily due to a drug supply issue. Read More

Pharma: Other news to note

Valeant Pharmaceuticals International Inc., of Laval, Quebec, completed the previously announced transaction in which a wholly owned subsidiary of Valeant Pharmaceuticals International would acquire Solta Medical Inc. at a price of $2.92 per share in cash. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe